Zydus Lifesciences bags USFDA nod for Lacosamide Injection; stock marginally up

1 Jul 2022 , 11:04 AM

The United States Food and Drug Administration (USFDA) has granted Zydus Lifesciences Ltd. (formerly Cadila Healthcare Ltd.) final approval to market Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL) single-dose vials (US RLD: Vimpat).

The injection of lacosamide is used to treat partial-onset seizures. It is also used in the treatment of primary generalized tonic-clonic seizures in conjunction with other medications. It reduces the number and severity of seizures by acting on the Central Nervous System (CNS).

The medication will be produced at the group’s injectables manufacturing facility in Jarod, India. Lacosamide Injection has a market value of USD 50 million (according to IQVIA MAT May 2022).

Since the beginning of the filing process in FY 2003-04, the group has received 316 approvals and has filed over 420* ANDAs.

At around 11.08 AM, Zydus Lifesciences was trading at Rs357.90 up by Rs1.15 or 0.32% from its previous closing of Rs356.75 on the BSE. The scrip opened at Rs357.25 and has touched intraday high and low of Rs357.95 and Rs354.50 respectively.